Progress in the mechanism and targeted drug therapy for COPD
#MMPMID33110061
Wang C
; Zhou J
; Wang J
; Li S
; Fukunaga A
; Yodoi J
; Tian H
Signal Transduct Target Ther
2020[Oct]; 5
(1
): 248
PMID33110061
show ga
Chronic obstructive pulmonary disease (COPD) is emphysema and/or chronic
bronchitis characterised by long-term breathing problems and poor airflow. The
prevalence of COPD has increased over the last decade and the drugs most commonly
used to treat it, such as glucocorticoids and bronchodilators, have significant
therapeutic effects; however, they also cause side effects, including infection
and immunosuppression. Here we reviewed the pathogenesis and progression of COPD
and elaborated on the effects and mechanisms of newly developed molecular
targeted COPD therapeutic drugs. Among these new drugs, we focussed on
thioredoxin (Trx). Trx effectively prevents the progression of COPD by regulating
redox status and protease/anti-protease balance, blocking the NF-?B and MAPK
signalling pathways, suppressing the activation and migration of inflammatory
cells and the production of cytokines, inhibiting the synthesis and the
activation of adhesion factors and growth factors, and controlling the cAMP-PKA
and PI3K/Akt signalling pathways. The mechanism by which Trx affects COPD is
different from glucocorticoid-based mechanisms which regulate the inflammatory
reaction in association with suppressing immune responses. In addition, Trx also
improves the insensitivity of COPD to steroids by inhibiting the production and
internalisation of macrophage migration inhibitory factor (MIF). Taken together,
these findings suggest that Trx may be the ideal drug for treating COPD.
free
free
free
